Mechanism of Action of Finerenone (Kerendia)
Introduction Finerenone is a nonsteroidal, selective mineralocorticoid receptor antagonist (MRA) approved for reducing the risk of cardiovascular and renal events in adults with chronic kidney disease (CKD) associated with type 2 diabetes mellitus (T2DM). Unlike steroidal MRAs such as spironolactone, finerenone offers greater mineralocorticoid receptor selectivity, minimizing off-target hormonal effects. Step-by-Step Mechanism of Action Pharmacokinetic … Read more
